In an impressive expansion of its capabilities, DINAMIQS, a Siegfried company renowned for its excellence in viral vector design and production, celebrated the launch of its cutting-edge cGMP manufacturing unit in Switzerland. Nestled in the Bio-Technopark in Zurich, this premiere facility promises a transformative leap in the landscape of viral vector-based gene therapies by integrating all stages of production — from molecular design to clinical-grade manufacturing — under a single roof. This strategic move fortifies Siegfried’s foothold in the burgeoning cell and gene therapy sector.
Innovative Facility Design and Capabilities
This pioneering facility, sprawling across 2,500 square meters, is uniquely curated to blend Research & Development (R&D), clinical, and commercial production processes. With production scaling up to 1,000 liters, the facility showcases a modular and segregated infrastructure powered by state-of-the-art closed, single-use technologies to meet the rigorous standards of Good Manufacturing Practice (GMP). Marcel Imwinkelried, the Chief Executive Officer of Siegfried, articulated their ambition to scale DINAMIQS’ potential, positioning it as a leader among Contract Development and Manufacturing Organizations (CDMOs) in the gene therapy domain.
Strategic Partnership with SEAL Therapeutics
In conjunction with this grand inauguration, DINAMIQS announced a collaborative venture with SEAL Therapeutics — a dynamic spin-off from the University of Basel’s Biozentrum. This alliance aims to accelerate the development of a groundbreaking gene therapy that targets the genetic anomalies responsible for causing LAMA2 related muscular dystrophy, a progressive and severe childhood ailment with no existing cure. Martin Kessler, CEO of DINAMIQS, highlighted the facility’s capability to deliver comprehensive solutions for viral vector production, optimizing time and cost for therapeutic developments.
– DINAMIQS’ facility offers complete viral vector therapy solutions under one roof, enhancing production efficiency.
– The collaboration with SEAL Therapeutics focuses on developing a gene therapy for a muscular dystrophy that currently lacks any treatment.
– DINAMIQS employs cutting-edge technologies that ensure scale and compliance to streamline therapeutic advancements.
The integration of R&D with clinical and commercial manufacturing in-house not only positions Siegfried as an influential player in the gene therapy sphere but also demonstrates a strategic alignment with industry needs for scalable and efficient production capabilities. This pioneering endeavor reflects a well-rounded response to current challenges in the viral vector domain, bringing the world of genetic therapies a step closer to delivering on its therapeutic promises. Such initiatives not only emphasize the importance of technological innovation but also underscore the necessity of fostering partnerships that drive the healthcare sector forward. Embracing this dual approach, Siegfried and DINAMIQS are not just driving growth but also contributing significantly to scientific advancements with the potential to transform lives.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
